MX2022006853A - Macrociclos para uso en el tratamiento de enfermedades. - Google Patents

Macrociclos para uso en el tratamiento de enfermedades.

Info

Publication number
MX2022006853A
MX2022006853A MX2022006853A MX2022006853A MX2022006853A MX 2022006853 A MX2022006853 A MX 2022006853A MX 2022006853 A MX2022006853 A MX 2022006853A MX 2022006853 A MX2022006853 A MX 2022006853A MX 2022006853 A MX2022006853 A MX 2022006853A
Authority
MX
Mexico
Prior art keywords
macrocycles
treating disease
methods
present disclosure
pharmaceutical compositions
Prior art date
Application number
MX2022006853A
Other languages
English (en)
Inventor
Wei Deng
Jane Ung
Evan W Rogers
Dayong Zhai
Jingrong J Cui
Vivian Nguyen
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=76091584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022006853(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of MX2022006853A publication Critical patent/MX2022006853A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems

Abstract

La presente divulgación se refiere a ciertos derivados macrocíclicos diaril quirales, composiciones farmacéuticas que los contienen y métodos para su uso en el tratamiento del cáncer.
MX2022006853A 2019-12-03 2020-12-02 Macrociclos para uso en el tratamiento de enfermedades. MX2022006853A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962943098P 2019-12-03 2019-12-03
US202063015937P 2020-04-27 2020-04-27
PCT/US2020/062859 WO2021113339A1 (en) 2019-12-03 2020-12-02 Macrocycles for use in treating disease

Publications (1)

Publication Number Publication Date
MX2022006853A true MX2022006853A (es) 2022-09-19

Family

ID=76091584

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006853A MX2022006853A (es) 2019-12-03 2020-12-02 Macrociclos para uso en el tratamiento de enfermedades.

Country Status (14)

Country Link
US (3) US11634433B2 (es)
EP (1) EP4069700A4 (es)
JP (1) JP2023504523A (es)
KR (1) KR20220133869A (es)
CN (1) CN114929710B (es)
AU (1) AU2020395136A1 (es)
BR (1) BR112022010702A2 (es)
CA (1) CA3163735A1 (es)
CO (1) CO2022008817A2 (es)
IL (1) IL293458A (es)
MX (1) MX2022006853A (es)
PE (1) PE20221485A1 (es)
TW (1) TW202134249A (es)
WO (1) WO2021113339A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114929710B (zh) 2019-12-03 2024-03-29 特普医药公司 用于治疗疾病的巨环
CN113336774B (zh) * 2021-06-25 2023-05-23 江南大学 作为trk抑制剂的取代的手性二芳基大环化合物
WO2024017380A1 (zh) * 2022-07-22 2024-01-25 南京明德新药研发有限公司 含三并环的大环类化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE526330T1 (de) * 2000-12-28 2011-10-15 Ono Pharmaceutical Co Heterotrizyklische verbindungen als antagonisten des crf-rezeptors
US8211891B2 (en) * 2008-04-30 2012-07-03 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors
CA2849999A1 (en) 2011-09-30 2013-04-04 Oncodesign S.A. Macrocyclic flt3 kinase inhibitors
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
US9714258B2 (en) * 2014-01-24 2017-07-25 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
JP6871903B2 (ja) * 2015-07-02 2021-05-19 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． プロテインキナーゼのモジュレーターとしてのキラルジアリール大環状分子
PL3728271T3 (pl) * 2017-12-19 2023-01-23 Turning Point Therapeutics, Inc. Związki makrocykliczne do leczenia chorób
US20210087206A1 (en) * 2017-12-19 2021-03-25 Turning Point Therapeutics, Inc. Macrocyclic kinase inhibitors and their use
TW201932472A (zh) * 2018-01-30 2019-08-16 大陸商上海吉倍生物技術有限公司 具有大環分子結構的化合物及其用途
CN114929710B (zh) 2019-12-03 2024-03-29 特普医药公司 用于治疗疾病的巨环

Also Published As

Publication number Publication date
PE20221485A1 (es) 2022-09-26
US11142533B2 (en) 2021-10-12
AU2020395136A1 (en) 2022-07-07
US20230322806A1 (en) 2023-10-12
US11634433B2 (en) 2023-04-25
CO2022008817A2 (es) 2022-09-20
TW202134249A (zh) 2021-09-16
CA3163735A1 (en) 2021-06-10
IL293458A (en) 2022-07-01
WO2021113339A1 (en) 2021-06-10
JP2023504523A (ja) 2023-02-03
CN114929710B (zh) 2024-03-29
CN114929710A (zh) 2022-08-19
BR112022010702A2 (pt) 2022-10-04
KR20220133869A (ko) 2022-10-05
US20210163499A1 (en) 2021-06-03
EP4069700A4 (en) 2023-05-17
US20210246145A1 (en) 2021-08-12
EP4069700A1 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
PH12020550901A1 (en) Macrocyclic compounds for treating disease
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2022006853A (es) Macrociclos para uso en el tratamiento de enfermedades.
MX2019001125A (es) Inhibidores de cinasa macrociclica.
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2017013142A (es) Terapia combinada para tratar cáncer.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
ZA201907225B (en) Treatment of her2 positive cancers
WO2019090347A8 (en) Adenosine pathway inhibitors for cancer treatment
MX2019003134A (es) Terapia de combinacion.
MX2023007162A (es) Macrociclos y sus usos.
MX2020001727A (es) Terapia de combinacion.
MX2023000503A (es) Macrociclos y su uso.
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
MX2019013862A (es) Terapia de combinacion.
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
WO2018208954A3 (en) Peptidomimetic macrocycles and uses thereof
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
AU2017264839A1 (en) 2-Anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.